Bank of Montreal Can Acquires 717,503 Shares of Bristol-Myers Squibb Co (BMY)

Bank of Montreal Can boosted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,862,162 shares of the biopharmaceutical company’s stock after buying an additional 717,503 shares during the period. Bank of Montreal Can owned about 0.36% of Bristol-Myers Squibb worth $363,924,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Bristol-Myers Squibb by 7.2% during the second quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock valued at $6,193,296,000 after acquiring an additional 7,517,623 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Bristol-Myers Squibb by 114.5% during the second quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock valued at $383,119,000 after acquiring an additional 3,695,485 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Bristol-Myers Squibb by 4,455.9% during the second quarter. Point72 Asset Management L.P. now owns 3,416,898 shares of the biopharmaceutical company’s stock valued at $189,091,000 after acquiring an additional 3,341,898 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Bristol-Myers Squibb by 419.0% during the second quarter. Schroder Investment Management Group now owns 3,851,748 shares of the biopharmaceutical company’s stock valued at $213,003,000 after acquiring an additional 3,109,664 shares during the period. Finally, MUFG Securities EMEA plc bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at $134,854,000. Hedge funds and other institutional investors own 72.28% of the company’s stock.

A number of research firms recently issued reports on BMY. Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, July 15th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Atlantic Securities raised Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price target for the company in a report on Wednesday, August 8th. Credit Suisse Group reaffirmed a “hold” rating and issued a $61.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 12th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $47.00 price target on shares of Bristol-Myers Squibb in a report on Thursday, June 21st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $62.95.

Shares of NYSE:BMY opened at $57.51 on Friday. The stock has a market cap of $101.47 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.70 and a beta of 0.98. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.40 and a quick ratio of 1.28.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.74 EPS. As a group, sell-side analysts expect that Bristol-Myers Squibb Co will post 3.62 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: What is the yield curve?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply